Ivacaftor deuterated

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein- -Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- BOSTON --(BUSINESS WIRE)--Apr. 1, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approximately 95% of people with CF in the U.S. are now eligible for treatment with a CFTR modulator. “This groundbreaking approval represents more than 20 years of innovation in CF, including testing over 600 variants in our laboratory, demonstrating clinical effects in large clinical trials, and studying younger people with CF so they can be treated as early as possible,” said Carmen Bozic , M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex . “With this label expansion, any variant that results in production of CFTR protein is now included in the ALYFTREK and TRIKAFTA labels, validating that these medicines can restore CFTR function and provide clinical benefit to patients regardless of where in the CFTR protein a variant is located. We thank the CF community and investigators for their trust and look forward to bringing ALYFTREK and TRIKAFTA to more patients than ever before.” For more information on ALYFTREK or TRIKAFTA, patient assistance programs, or eligibility details, visit ALYFTREK.com, TRIKAFTA.com, VertexGPS.com or vertextreatments.com. IMPORTANT SAFETY INFORMATION WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE Elevated transaminases have been observed in patients treated with ALYFTREK. TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Cases of liver failure leading to transplantation and death have been reported in both clinical trials and the postmarketing setting in patients with and without a history of liver disease taking TRIKAFTA, a fixed-dose combination drug containing elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA), the same or similar active ingredients as ALYFTREK. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA. Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating ALYFTREK or TRIKAFTA, then every month during the first 6 months of treatment, every 3 months for the next 12 months, and at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or liver function test (LFT) elevations at baseline. Interrupt ALYFTREK or TRIKAFTA for significant elevations in LFTs or in the event of signs or symptoms of liver injury. Consider referral to a hepatologist. Follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If resolved, resume treatment only if benefit is expected to outweigh risk. Closer monitoring is advised after resuming treatment. ALYFTREK or TRIKAFTA should not be used in patients with severe hepatic impairment (Child- Pugh Class C ). ALYFTREK or TRIKAFTA is not recommended in patients with moderate hepatic impairment (Child- Pugh Class B ). ALYFTREK or TRIKAFTA should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced dosage and monitor patients closely. WARNINGS AND PRECAUTIONS DRUG-INDUCED LIVER INJURY AND LIVER FAILURE Elevated transaminases have been observed in patients treated with ALYFTREK. TRIKAFTA can cause serious and potentially fatal drug-induced liver injury. Liver failure leading to transplantation and death has been reported in patients with and without a history of liver disease taking TRIKAFTA. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of TRIKAFTA Assess LFTs in all patients prior to initiating ALYFTREK or TRIKAFTA, then every month during the first 6 months of treatment, every 3 months for the next 12 months, and at least annually thereafter. Consider more frequent monitoring for patients with a history of liver disease or LFT elevations at baseline, or a history of elevated LFTs with drugs containing ELX, TEZ, and/or IVA Interrupt ALYFTREK or TRIKAFTA in the event of signs or symptoms of liver injury, which may include: Significant elevations in LFTs (e.g., ALT or AST >5x the upper limit of normal (ULN) or ALT or AST >3x ULN with bilirubin >2x ULN) Clinical symptoms suggestive of liver injury (e.g., jaundice, right upper quadrant pain, nausea, vomiting, altered mental status, ascites) Consider referral to a hepatologist and follow patients closely with clinical and laboratory monitoring until abnormalities resolve. If resolved, and if benefit is expected to outweigh risk, resume treatment with close monitoring ALYFTREK and TRIKAFTA should not be used in patients with severe hepatic impairment, are not recommended in patients with moderate hepatic impairment, and should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced dosage and monitor patients closely Significant elevations in LFTs (e.g., ALT or AST >5x the upper limit of normal (ULN) or ALT or AST >3x ULN with bilirubin >2x ULN) Clinical symptoms suggestive of liver injury (e.g., jaundice, right upper quadrant pain, nausea, vomiting, altered mental status, ascites) HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS Hypersensitivity reactions, including cases of angioedema and anaphylaxis, have been reported in the postmarketing setting for TRIKAFTA. If signs or symptoms of serious hypersensitivity reactions develop during treatment, discontinue ALYFTREK or TRIKAFTA and institute appropriate therapy. Consider benefits and risks to determine whether to resume treatment PATIENTS WHO DISCONTINUED OR INTERRUPTED ELX-, TEZ-, OR IVA-CONTAINING DRUGS DUE TO ADVERSE REACTIONS ALYFTREK There are no available safety data for ALYFTREK in patients who previously discontinued or interrupted treatment with drugs containing ELX, TEZ, or IVA due to adverse reactions. Consider benefits and risks before using ALYFTREK in these patients and if used, closely monitor for adverse reactions INTRACRANIAL HYPERTENSION (IH) IH has been reported in the postmarketing setting with TRIKAFTA, which contains the same or similar active ingredients as ALYFTREK. Clinical manifestations of IH include headache, blurred vision, diplopia, and potential vision loss; papilledema can be found on fundoscopy. If an unusual headache or visual disturbances occur during treatment, and IH is suspected, interrupt treatment and refer for prompt medical evaluation. Consider benefits and risks to determine whether to resume treatment. Patients should be monitored until IH resolution and for recurrence. Patients with elevated vitamin A levels may be at increased risk NEUROPSYCHIATRIC EVENTS, INCLUDING SUICIDAL THOUGHTS AND BEHAVIORS Serious neuropsychiatric events, including symptoms of anxiety, depression, suicidal ideation and behavior, and sleep disturbances, have been reported in the postmarketing setting in patients with and without a previous history of neuropsychiatric symptoms taking ALYFTREK or TRIKAFTA. Symptoms may occur within the first 3 months of treatment. Assess patients for baseline neuropsychiatric symptoms and monitor for new or worsening symptoms. Consider the benefits and risks to determine if treatment should be interrupted at symptom occurrence or resumed with symptom improvement DRUG INTERACTIONS Use With CYP3A Inducers Following concomitant use of strong or moderate CYP3A inducers with ALYFTREK, exposures of vanzacaftor, TEZ, and deutivacaftor were decreased, which may reduce ALYFTREK effectiveness. Concomitant use with strong or moderate CYP3A inducers is not recommended Exposure to IVA is significantly decreased and exposure to ELX and TEZ are expected to decrease with concomitant use of CYP3A inducers, which may reduce effectiveness of TRIKAFTA. Concomitant use with strong CYP3A inducers is not recommended Use With CYP3A Inhibitors Exposure to vanzacaftor, TEZ, and deutivacaftor or ELX, TEZ, and IVA are increased when used concomitantly with strong or moderate CYP3A inhibitors. The dose of ALYFTREK or TRIKAFTA should be reduced when used concomitantly with moderate or strong CYP3A inhibitors CATARACTS Non-congenital lens opacities have been reported in pediatric patients treated with TRIKAFTA, which contains IVA (similar to an active ingredient in ALYFTREK). Baseline and follow-up ophthalmological examinations are recommended in pediatric patients ADVERSE REACTIONS ALYFTREK Serious adverse reactions that occurred more frequently with ALYFTREK than with ELX/TEZ/IVA in 2 or more patients (≥0.4%) were influenza (1.5%), increased AST (0.4%), increased GGT (0.4%), depression (0.4%), and syncope (0.4%) The most common adverse reactions occurring in ≥5% of patients and at a frequency higher than ELX/TEZ/IVA by ≥1% were cough, nasopharyngitis, upper respiratory tract infection (URTI), headache, oropharyngeal pain, influenza, fatigue, increased ALT and AST, rash, and sinus congestion TRIKAFTA Serious adverse reactions that occurred more frequently in patients treated with TRIKAFTA compared to placebo included rash (1% vs <1%) and influenza (1% vs 0%) The most common adverse reactions occurring in ≥5% of patients treated with TRIKAFTA and at a rate higher than placebo by ≥1% were headache; URTI; abdominal pain; diarrhea; rash; increased ALT, blood creatine phosphokinase, AST, and blood bilirubin; nasal congestion; rhinorrhea; rhinitis; influenza; sinusitis; and constipation USE IN SPECIFIC POPULATIONS PEDIATRIC USE Safety and effectiveness have not been established for ALYFTREK in patients <6 years, nor for TRIKAFTA in patients <2 years. The use in children under these ages is not recommended Please see full Prescribing Information, including Boxed WARNING, for ALYFTREK and TRIKAFTA. About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 112,000 people, including approximately 97,000 people in the United States , Europe , Australia and Canada . CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving. Learn more about the importance of sweat chloride (SwCl) in cystic fibrosis. Today Vertex CF medicines are treating over 75,000 people with CF across more than 60 countries on six continents. This represents approximately 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston , with international headquarters in London . Additionally, the company has research and development sites and commercial offices in North America , Europe , Australia , Latin America and the Middle East . Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex 's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Carmen Bozic , M.D., in this press release, statements regarding the anticipated benefits of ALYFTREK and TRIKAFTA, expectations regarding the eligible patient population, and expectations for patient access to ALYFTREK and TRIKAFTA. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, that patients may not have access to ALYFTREK or TRIKAFTA on the anticipated timeline, and other risks listed under the heading “Risk Factors” in Vertex 's annual report and in subsequent filings filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com and www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) View source version on businesswire.com: https://www.businesswire.com/news/home/20260401690804/en/ Vertex Pharmaceuticals Incorporated Investors: InvestorInfo@vrtx.com Media: mediainfo@vrtx.com or U.S. : 617-341-6992 or International: +44 20 3204 5275 Source: Vertex Pharmaceuticals Incorporated

如果只看结果，Vertex 在囊性纤维化（cystic fibrosis, CF）领域的成功，似乎是靠几款重磅药堆出来的：Kalydeco、Orkambi、Symdeko、Trikafta、Alyftrek。但如果往深处看，Vertex 真正厉害的地方，并不只是“做出了一款药”，而是它围绕 CF 这个疾病，建立了一套极其清晰、且被长期验证成功的研发策略：围绕单一致病机制深耕、按突变机制分层推进、通过组合疗法持续迭代，并不断用下一代产品和新技术路线延长整个 franchise 的生命周期。一、先看疾病本身：CF 患者是谁，患者规模有多大？ 囊性纤维化是一种由 CFTR 基因突变引起的罕见遗传病，可累及肺、胰腺、肠道、肝脏和生殖系统等多个器官。患者最典型的问题是气道分泌物异常黏稠，导致反复肺部感染、慢性炎症、进行性肺功能下降；同时常伴有胰腺外分泌功能不全、营养吸收障碍、体重增长不良，部分患者还会出现 CF 相关糖尿病、肝病和生育问题。CF 因此不是一个单纯“肺病”，而是一个需要长期综合管理的多系统遗传病。  从患者画像看，CF 过去常被视为“儿童病”，但这个印象已经明显过时。Cystic Fibrosis Foundation 的官方资料显示，美国现在已有接近 4 万名 儿童和成人 CF 患者；全球范围内，已有约 10.5 万名 患者在 94 个国家 被诊断为 CF。美国 CF 患者中，约 60% 已经年满 18 岁。这意味着今天的 CF 已经不只是儿童重症市场，而是一个覆盖儿童、青少年和成人的长期慢病市场。欧洲方面，European Cystic Fibrosis Society Patient Registry 显示，其数据库已覆盖 54,000 多名 患者，来自 46 个国家。  也就是说，CF 有一个非常特别的市场特征：它是罕见病，但患者基数又足够大，足以支撑全球化、高价值、可持续迭代的精准治疗市场；与此同时，它又高度依赖突变分层，非常适合“先在小人群 proof-of-concept，再向大人群扩展”的研发策略。 这正是 Vertex 能把 CF 做成行业标杆的现实基础。二、Vertex 的第一个战略判断：不做外围改善，直接押注病因治疗 很多公司面对 CF 这样的疾病，首先想到的可能是改良抗感染、祛痰、抗炎或营养支持，因为这类路径更熟悉、风险更低。但 Vertex 一开始就没有把重点放在“外围支持治疗优化”，而是直接瞄准 CFTR 本身。这意味着它不是在治疗疾病后果，而是在试图纠正致病源头。 这个选择的战略意义非常大。因为一旦把研发中心放在 CFTR 这个致病蛋白上，公司后续就不再只是做一个单点项目，而是有机会围绕同一个核心机制，不断衍生出一代、二代、三代产品。后来的事实证明，Vertex 的 CF 管线，正是沿着这条路线展开的。三、第二个战略判断：先搭“发现平台”，而不是先赌单个分子 Vertex 在 CF 领域最值得研究的一点，是它从一开始就不是简单押一个先导化合物，而是和 Cystic Fibrosis Foundation 及其研发体系一起，围绕 CFTR 构建发现和筛选能力。CFF 官方历史明确记载，基金会在 2000 年向 Aurora Biosciences 投资 4000 万美元；Aurora 后来并入 Vertex，这笔投资后来被广泛视为“venture philanthropy”最成功的案例之一。  从研发策略上说，这一步非常关键。因为 CF 不是一个“一个药打所有患者”的疾病，而是一个同一基因、不同突变、不同失功能机制并存的疾病。于是 Vertex 需要的不是一个偶然有效的分子，而是一套能持续识别不同功能缺陷、并能围绕不同缺陷设计药物类别的体系。也正是在这种思路下，CFTR 调节剂逐渐形成了两个基本方向：一类是 potentiator（增效剂），提升已经到达细胞膜的 CFTR 通道活性；另一类是 corrector（校正剂），帮助异常折叠/转运的 CFTR 蛋白更好到达细胞表面。这意味着 Vertex 很早就不是在做一个产品，而是在做一个机制平台。四、第三个战略判断：先在“小而准”的人群中验证机制 2012 年，Vertex 推出了 Kalydeco（ivacaftor），这是 CF 领域第一款真正意义上的病因治疗药物，也被认为是首个成功上市的 CFTR potentiator。Kalydeco 最初针对的是 G551D 等 gating mutation 患者，而不是最大人群 F508del。 Kalydeco（ivacaftor） 从表面看，这像是在做一个小市场；但从策略上看，这是非常聪明的一步。因为 gating mutation 的问题相对更“纯粹”：CFTR 蛋白已经在细胞膜上，只是开关效率不足。对这类患者，potentiator 的作用最容易在人体里被观察到，也最容易形成清晰、干净的 proof-of-concept。换句话说，Vertex 并没有一开始就去攻最复杂、最难啃的人群，而是先在最容易验证机制成立的患者群体中打下第一场关键胜仗。 这其实是精准医学里很经典的打法：先在最合适的分层人群里证明机制正确，再逐步扩大适用边界。五、第四个战略判断：机制一旦成立，立刻转向最大患者群 如果 Vertex 停留在 Kalydeco，它已经能被写进药物研发史。但 Vertex 显然不是满足于做出一款“科学上漂亮、商业上中等规模”的罕见病药，而是迅速把主战场转向 F508del——CF 中最常见、也是机制最复杂的突变类型之一。 这体现了 Vertex 研发策略中非常成熟的一点：它不是长期停留在“最容易成功的小亚群”，而是在机制成立后，立刻向患者数最大、临床价值最大、市场壁垒也最高的人群推进。 沿着这条路线，Vertex 先后推出了Orkambi（lumacaftor/ivacaftor） 和 Symdeko/Symkevi（tezacaftor/ivacaftor）。它们的真正战略价值，并不只是多了两个新产品，而是标志着 Vertex 成功把平台从“小突变亚群”推进到了 CF 的主流人群。  这一步非常像一个成熟药企的打法：先用第一代产品建立范式，再用后续产品迅速吞下核心市场。 lumacaftor tezacaftor六、第五个战略判断：把组合疗法做成“机制模块化”，而不是简单拼药 Vertex 在 CF 领域最值得同行研究的地方之一，是它对组合疗法的理解非常深。很多公司做组合，是两个药硬拼，希望疗效叠加；但 Vertex 做组合，核心是围绕 CFTR 的不同缺陷环节进行功能分工： potentiator：让已到达膜上的通道更会工作 corrector：让更多功能性蛋白抵达膜上 双 corrector + potentiator：在复杂突变背景下进一步提升总体功能恢复水平 这套逻辑在 Trikafta（elexacaftor/tezacaftor/ivacaftor） 上达到顶峰。Vertex 后续又在 2024 年 12 月 获得 FDA 对 Alyftrek（vanzacaftor/tezacaftor/deutivacaftor） 的批准；Vertex 官方称其为 once-daily、next-in-class 的三联 CFTR 调节剂，适用于 6 岁及以上、至少携带一个响应性突变的患者，并新增覆盖 31 个 其他调节剂尚未覆盖的响应性突变。  从研发策略角度看，这意味着 Vertex 已经把 CFTR 调节做成了一种模块化工程：不是“做出一款药就结束”，而是围绕同一机制，把不同功能模块不断优化、重组、升级。这也是为什么它能从单药走到双联，再走到三联，而且每一代都不是简单换包装，而是实质性的机制增强。 elexacaftor vanzacaftor deutivacaftor七、第六个战略判断：Trikafta 不是终点，而是“版本管理”的起点 很多公司做到 Trikafta 这种级别，往往会进入“收获期思维”——重点变成全球商业化、报销覆盖和利润最大化。但 Vertex 并没有停下来，而是继续推出下一代产品 Alyftrek。Vertex 官方披露显示，Alyftrek 已在美国获批，并随后在英国、欧盟、加拿大等市场获批或完成关键进展；2026 年 2 月的公司财报更新也明确提到，Alyftrek 已成为最新上市的 CFTR modulator，并已覆盖多个主要市场。  这背后体现的是非常成熟的生命周期管理思维： 第一，继续提升给药便利性，例如 once-daily；第二，继续扩大响应突变覆盖范围；第三，用下一代产品接住上一代产品的市场和专利生命周期，延长整个平台的护城河。 所以，Vertex 在 CF 上不是“出了一款 blockbuster”，而是在运营一个持续升级的系统。八、第七个战略判断：不只吃下 90% 的人群，还继续追最后那 10% Vertex 的官方 pipeline 页面明确表示，其目标不仅是服务现有可由 CFTR modulator 覆盖的人群，也要继续推进针对无法从现有调节剂获益患者的方案。当前最具代表性的项目就是 VX-522：一种通过脂质纳米颗粒递送到肺部的 CFTR mRNA 疗法。Vertex 官方资料显示，VX-522 正处于 Phase 1/2，公司计划在 2026 年下半年 分享数据。  这一点非常能说明 Vertex 的战略格局。如果只从短期收入看，公司完全可以继续围绕已上市 modulator 深耕；但从长期平台统治力看，它必须继续覆盖那部分没有可调节 CFTR 蛋白、或难以从现有 modulator 获益的患者。也就是说，Vertex 的目标不是“把现有市场榨干”，而是“把整个疾病地图尽可能完整地覆盖”。九、再回头看，Vertex 的 CF 成功不是偶然，而是几条策略叠加的结果 如果把 Vertex 在 CF 领域近三十年的研发史浓缩成几条核心方法论，我觉得可以总结为： 第一，靶点极度聚焦。长期围绕 CFTR，不轻易偏航。  第二，先做平台，再出产品。早期就围绕疾病机制和筛选体系建立持续发现能力，而不是押一把单个分子。  第三，先在最合适的小人群中验证机制。Kalydeco 针对 gating mutation，不是因为市场最大，而是因为机制最容易被清晰验证。  第四，机制成立后，迅速向最大患者群推进。从少数 gating mutation 扩展到 F508del 主流市场，是 Vertex 真正放大商业价值的关键。  第五，组合疗法不是拼凑，而是模块化设计。这是 Vertex 能持续推出双联、三联并代际升级的底层原因。  第六，产品上市只是开始，不是结束。从 Trikafta 到 Alyftrek，体现的是平台持续延寿，而不是单次收获。  第七，最后那部分未满足需求也不能放弃。VX-522 显示 Vertex 仍在向 non-modulator 路线扩边界。 十、结论：Vertex 不是“做出了几款 CF 药”，而是把 CF 做成了一套战略模板 所以，如果要评价 Vertex 的 CF 研发史，最值得学习的不是某一个分子的发现过程，而是它展现出了一种极其罕见的战略一致性： 它在一个机制足够清晰的疾病上长期深耕；它先搭平台，再持续产出产品；它用患者分层提升临床成功率；它用组合疗法不断扩大疗效和覆盖范围；它用下一代产品和新技术路线延长 franchise 生命周期。  本质上，Vertex 在 CF 上做成的，不只是一个产品线，而是一套精准医学时代的平台化研发范式。这也是为什么在生物医药行业里，Vertex 的 CF 故事常常被当作教科书案例：它证明了只要机制抓得足够准、策略足够稳定、迭代足够持续，一个罕见病也可以被做成全球最成功的创新药 franchise 之一。